Cash Flow Statement

Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization EBIAT Leases Long-Term Debt Issuances Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares Issued Shares Outstanding Shares Outstanding Shares Repurchased

Ratios

Cullinan Therapeutics (CGEM) Preferred Shares Issued (2022 - 2023)

Cullinan Therapeutics has reported Preferred Shares Issued over the past 2 years, most recently at $1.8 million for Q1 2023.

Quarterly results put Preferred Shares Issued at $1.8 million for Q1 2023, up 128.12% from a year ago — trailing twelve months through Dec 2023 was $1.8 million (down 23.16% YoY), and the annual figure for FY2023 was $1.8 million, down 23.16%.
Preferred Shares Issued for Q1 2023 was $1.8 million at Cullinan Therapeutics, up from $175000.0 in the prior quarter.
Over the last five years, Preferred Shares Issued for CGEM hit a ceiling of $1.8 million in Q1 2023 and a floor of $175000.0 in Q4 2022.